Clinical Trials Logo

Glucose Intolerance clinical trials

View clinical trials related to Glucose Intolerance.

Filter by:

NCT ID: NCT02082756 Withdrawn - Prediabetes Clinical Trials

Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment

Start date: November 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

NCT ID: NCT01093677 Withdrawn - Clinical trials for Impaired Glucose Tolerance

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance

LIM
Start date: March 2010
Phase: Phase 1
Study type: Interventional

LIM-0705 will gain results on the effects of LIM-0705 on Male Subjects with Impaired Glucose Tolerance

NCT ID: NCT00845559 Withdrawn - Obesity Clinical Trials

The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

Start date: August 2008
Phase: Phase 4
Study type: Interventional

The primary aim of this study is to evaluate the effect of exenatide on daily glycemic excursions obtained by continuous glucose monitoring system (CGMS). The CGMS summary parameters that we are most interested in include: - The percent of glucose values above 140 mg/dl and/or AUC of glucose values above 140 mg/dl - AUC of glucose values over 100 mg/dl during three days - Maximal meal-related glucose excursions - Three-day mean glucose (including low readings - below 100 mg/dl) Secondary Study Endpoints: Secondary endpoints will include: - glucose tolerance status as assessed by OGTT - Vascular function scores as assessed by PAT, FMD and step test. - Biochemical markers of vascular health, including inflammatory markers, markers of oxidative stress and microalbuminuria. - Changes in BMI

NCT ID: NCT00306826 Withdrawn - Clinical trials for Glucose Metabolism Disorders

Pioglitazone in Impaired Glucose Tolerance

Start date: n/a
Phase: Phase 4
Study type: Interventional

In patients with impaired glucose tolerance (IGT), the researchers want to study the relative effects of pioglitazone, simvastatin, or the combination of both on: - intima media thickness (IMT) as an easily assessed marker of atherosclerosis - heart rate variability (HRV) as a marker of autonomic neuropathy - flow-mediated vasodilatation (FMD) of the brachial artery as a marker of endothelial function - vascular and metabolic lab parameters